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Abstract
Objective. Macrophage migration inhibitory factor (MIF) is considered as an important mediator in the pathogenesis of
neoplasia. The aim of the present study was to evaluate whether MIF could be used as a marker for hepatocellular carcinoma
(HCC) detection. Material and methods. Biodistribution and whole-body autoradiography studies of
131I-labeled anti-
MIF monoclonal antibody (McAb) and
131I-labeled control IgG were performed. The HCC-bearing mice were injected
with 3.7 MBq of each agent and killed at 24, 48, and 72 h postinjection (p.i.). The organs, blood, and HCC tissues were
removed from model mice, weighed, and counted using a gamma-counter. The expression of MIF mRNA and protein
within HCC tissues was conﬁrmed by RT-PCR and immunohistochemistry. Results. HCCs in model mice could be
adequately visualized at 24 h p.i. The target-to-non-target (T/NT) ratios were 6.72 ± 1.09 (24 h), 9.85 ± 0.81 (48 h), and
12.31 ± 0.57 (72 h) for
131I-labeled anti-MIF McAb group, whereas in the control group of
131I-IgG, T/NT ratios were
4.65 ± 0.63 (24 h), 6.12 ± 0.60 (48 h), and 8.23 ± 0.35 (72 h) (p < 0.05). MIF mRNA expression was twofold higher in the
HCC tissues than in the healthy liver tissues. MIF protein expression was much higher in the HCC tissues than in controls.
Conclusions. Our ﬁndings suggested that
131I-anti-MIF McAb could be rapidly and speciﬁcally localized in tumors. Thus,
M I Fc o u l db eu s e da sam a r k e rf o rH C Ct u m o rd e t e c t i o n .
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Introduction
Hepatocellular carcinoma (HCC) is one of the most
frequently reported malignant tumors in contempo-
rary medicine and is becoming increasingly signiﬁ-
cant in clinical research [1,2]. Detection of HCC at an
earlier stage is very important for patient’s prognosis.
For decades, a-fetoprotein (AFP) has been used as a
serum marker for HCC; however, it is insufﬁcient for
HCC screening. The ability of abdominal imaging
to detect HCCs has improved dramatically over the
last few decades. Although ultrasonography (US) and
computed tomography (CT) usually accurately depict
HCC [3], attempts to improve the methods of staging
and follow-up for patients with known HCC have
led to the evaluation of nuclear imaging systems in
HCC [4]. Therefore, efforts are being made to iden-
tify alternative tracers for screening and staging HCCs
in patients at risk.
Macrophage migration inhibitory factor (MIF)
has been considered as the most interesting fac-
tor because of its diverse functions [5]. Originally
described as a product of activated T cells that
inhibits the migration of macrophages, MIF was
subsequently found to be involved in the develop-
ment of pathological changes associated with several
acute and chronic inﬂammatory disease processes,
such as acute respiratory distress syndrome [6],
septic shock [7], rheumatoid arthritis [8], athero-
sclerosis [9], glomerulonephritis [10], and allograft
rejection [11]. Recent studies have shown that MIF
plays an important role in the tumor formation [12].
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and tumor angiogenesis [13], and over-expression of
MIF has been reported in various types of cancers,
including prostate tumors, breast cancer, colon car-
cinomas, HCCs, and glioblastoma. In the current
study, we labeled anti-MIF monoclonal antibody
(McAb) with radioiodine Na
131I in order to deter-
mine the role of MIF in HCC progression. In addi-
tion, we investigated its biodistribution and imaging
characteristics in vivo using an HCC tumor-bearing
model in mice. The results of our study indi-
cated that MIF could be used as a supplementary
biomarker for the detection of HCCs.
Material and methods
Radioiodination of anti-MIF McAb
All commercially available chemicals were of ana-
lytic grade and anti-MIF McAb (R&D Systems),
and IgG (ZSGB-BIO) were of pharmaceutical grade.
Anti-MIF McAb and control IgG were iodinated
with Na
131I( s p e c i ﬁc activity 37 MBq/mg, China
Institute of Atomic Energy) using the Iodogen tech-
nique. Radioiodinated anti-MIF McAb and con-
trol IgG were separated from free iodine using size
exclusion columns (Sephadex G-25, Pharmacia).
The speciﬁc activity of radioiodinated anti-MIF
McAb is 28.56 GBq/mmol, and that of radioiodi-
nated IgG is 27.63 GBq/mmol. The radiochemical
purity of radioiodinated anti-MIF McAb is >95% (as
revealed by paper chromatography), and that of
radioiodinated IgG is >95% (paper chromatogra-
phy). The immunological activities of
131I-labeled
anti-MIF McAb were conﬁrmed by ELISA (enzyme-
linked immunosorbent assay) (data not shown).
Preparation of tumor-bearing animal model
Cell culture and all animal experiments were per-
formed in accordance with the principles of the
institutional, national, and international guidelines
for humane use of animals for research. The HCC
tumor models were established by subcutaneous
injection of 5  10
6 H22 tumor cells into the front
ﬂank of female severe combined immunodeﬁcient
(SCID) mice (20–25 g, 6–8 weeks, Animal Center
of Shandong University). Thyroid uptake was
blocked by the addition of potassium iodide to the
drinking water (0.1%) starting from 1 day before
the experiments. When the tumor volume reached
500–600 mm
3 (4 weeks after inoculation), the
tumor-bearing nude mice were used for biodistribu-
tion and gamma imaging studies.
Biodistribution of
131I-anti-MIF McAb
The HCC tumor-bearing mice (24 mice/group)
were injected with 3.7 MBq
131I-anti-MIF McAb
or
131I - I g Gi n0 . 2m lo fP B Sv i at h et a i lv e i nt o
evaluate the distribution in major organs of mice.
T h em i c ew e r es a c r i ﬁced at 24, 48, and 72 h post-
injection (p.i.). Blood, heart, liver, spleen, kidney,
brain, lung, intestine, muscle, bone, and tumor were
harvested, weighed, and measured for radioactivity
in a gamma-counter (1480 Wizard 3, PerkinElmer
L i f eS c i e n c e s ,B o s t o n ,M A ,U S A ) .O r g a nu p t a k e
was calculated as the percentage of injected dose per
gram of tissue (%ID/g). Values were expressed as
mean ± SD (n = 8/group).
Whole-body autoradiography
For whole-body autoradiography imaging, the HCC
tumor-bearing mice were anesthetized with an intra-
peritoneal injection of sodium pentobarbital at a dose
of 45 mg/kg. Each animal was administered with
3.7 MBq of the
131I-anti-MIF McAb or
131I-IgG in
0.2 ml of PBS (n = 4/group). Mice were placed on
their back on a storage phosphor screen plate in
subdued light. Each mouse was exposed to the plate
for 25 min. When the exposure needed to be stopped,
the plate was immediately covered with an opaque
plastic sheet, transferred to a scanner, and scanned by
using typhoon trio + (laser red, 633 nm; pixel size,
200 mm; phosphor mode: best sensitivity). Serial
images were acquired at 24, 48, and 72 h p.i.
RT-PCR
The expression of MIF mRNA was evaluated by
RT-PCR. Total RNA was isolated from HCC tissues
andhealthylivertissuesusingTRIzolreagent(Invitro-
gen Life Technologies, Carlsbad, CA, USA), and
DNA contaminant was removed by treatment with
DNase I (Invitrogen Life Technologies, Carlsbad,
CA, USA) according to the manufacturer’s instruc-
tions. Total RNA (5 mg) was reverse transcribed by
using Revert Aid  First Strand cDNA Synthesis Kits
(Fermentas), cDNAs ampliﬁed with murineMIF spe-
ciﬁc primer using TaKaRa PCR Ampliﬁcation Kit
(TaKaRa). The primers were designed as follows:
MIF (368 bp), sense primer, 5¢-CCATGCC-
TATGTTCATCGTG-3¢; and antisense primer,
5¢-GAACAGCGGTGCAGGTAAGTG-3¢. Cycling
conditions for ampliﬁcation were as follows: 4 min
denaturation step at 94C, followed by 35 cycles of
30 s at 94C, 1 min at 55C, and 1 s at 72C.
PCR products were analyzed on 1.5% agarose gels
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ments were performed in duplicate, and they were
repeated at least three times. GAPDH mRNA
expression was used as a loading control.
Histological and immunohistochemical analyses
HCC tissues and healthy liver tissues were ﬁxed in
10% PBS-buffered formalin, and parafﬁn sections
were stained with H&E and examined by light micros-
copy to assess the histological changes. Immunohis-
tochemical analysis was performed using a SP-9002
Histostain -Plus kit (ZSGB-BIO) according to the
manufacturer’s protocol. The sections were micro-
scopically examined and the positively stained ﬁelds
were observed. Ten ﬁelds per each section were
observed.
Statistical analysis
The data were analyzed using SPSS11.0 software.
Statistical analysis was performed using the unpaired
Student’s t-test. Difference was considered statisti-
cally signiﬁcant when p was <0.05, and two-sided.
All data were expressed as the means ± standard
deviation (SD).
Result
Accumulation in the HCC tissues
The concentration of
131I-anti-MIF McAb or
131I-IgG
in the HCC tissues was expressed as percentage of the
initial dose (%ID/g). As shown in Figure 1A, both the
radiopharmaceuticals signiﬁcantly localized at sites of
HCC tissues at 24 h p.i. The uptake of
131I-anti-MIF
McAb in HCC tumors was 0.214 ± 0.021%ID/g at
24 h p.i. and retained to 0.086 ± 0.0013%ID/g at 72 h
p.i. (n = 8/group). The uptake of
131I-anti-MIF McAb
wassigniﬁcantlyhigherthan thatof
131I-IgG(p< 0.05).
Target-to-non-target (T/NT) ratio for the
131I-anti-
MIF McAb group was 6.72 at 24 h and increased
continuously to 12.32 at 72 h. On the other hand,
the T/NT ratio for the
131I-IgG group was 4.65 at 48 h
and reached 8.23 at 72 h.
131I-anti-MIF McAb group
showed the highest uptake (p < 0.05, see Figure 1B).
Target-to-blood (T/B) ratios for the
131I-anti-MIF
McAb group were 1.39 ± 0.21, 2.45 ± 0.13, and
2.79 ± 0.21 at 24, 48 and 72 h p.i., respectively.
The T/B ratios for the
131I-anti-MIF McAb group
were signiﬁcantly higher than that of
131I-IgG group
(p < 0.05, see Figure 1C).
Taken together, the data indicated that the
131I-labeled anti-MIF McAb was more speciﬁc and
suitable for targeting HCC than the
131I-labeled IgG
antibody.
Imaging of HCC
The whole-body autoradiography images of the two
radiotracers at 24, 48 and 72 h p.i. were shown
in Figure 2. The HCC tumors of
131I-labeled
anti-MIF McAb were clearly visible at 24 and
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Figure 1. (A) Accumulation of
131I-anti-MIF McAb and
131I-IgG
in the hepatocellular carcinoma (HCC) tissues (%ID/g). Values are
means ± SD, n = 8 in all groups; *p < 0.05 vs.
131I-IgG. (B) Change
of T/NT in the HCC tissues of
131I-anti-MIF and
131I-IgG McAb
groups. Values are means ± SD, n = 8 in all groups; *p < 0.05 vs.
131I-IgG. (C) Change of T/B of
131I-anti-MIF McAb and
131I-IgG
in HCC tissues. Values are means ± SD, n = 8 in all groups;
*p < 0.05 vs.
131I-IgG.
722 C. Zhang et al.48 h p.i., with high contrast to the contralateral
background. Comparative analysis of the scintigrams
obtained at the three time points showed that the
131I-anti-MIF McAb group had remarkably clear
images than those of the
131I-IgG group; this ﬁnd-
ing was in accordance with the high T/NT ratio
(p < 0.05). These ﬁndings also indicate that the
131I-labeled anti-MIF McAb had higher speciﬁcity
for targeting HCC than that of the
131I-labeled IgG
antibody.
MIF mRNA expression in HCC and healthy liver tissues
To conﬁrm that the high intake of
131I-labeled anti-
MIF McAb in HCC tissues was due to the high
expression of MIF in locus, we analyzed the expression
of MIF in HCC tissues and healthy liver tissues. As
shown in Figure 3, there were little changes in MIF
gene expression pattern in healthy liver tissues at all the
three time points. However, MIF mRNA expression in
HCC tissues was twofold higher than that in healthy
liver tissues at 24 h p.i. (p < 0.05). The MIF mRNA
levels in HCC tissues remained elevated up to 72 h
p . i . ,i nc o n t r a s tt oe x p r e s s i o ni nh e a l t h yl i v e rt i s s u e s
(p < 0.05). MIF was secreted from many kind of cells
within tumor tissues, including activated lymphocytes,
macrophages, and tumor cells; these cells may produce
high levels of MIF as is noted in HCC cases.
MIF protein expression
Immunohistochemistry analysis showed that MIF
was highly expressed in the HCC tissues (Figure 4).
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Figure 2. Images ofthe hepatocellular carcinoma(HCC)micemodel.The
131I-anti-MIF McAbgrouphad clearimages inaccordancewith the
high T/NT ratio.
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Figure 3. The expression of MIF mRNA in hepatocellular carci-
noma (HCC) and healthy liver tissues. There were little changes in
MIF gene expression in healthy liver tissues at the three time
points. However, there was a twofold increase in MIF mRNA
expression in HCC tissues at 24 h compared with healthy liver
tissues (p < 0.05). The MIF mRNA levels in HCC tissues were
keeping at a high level until 72 h compared with healthy liver
tissues (p < 0.05). Semi-quantitative RT-PCR was performed in
duplicate to minimize experimental error on the value calculated.
All columnar values were expressed as means and standard devia-
tions. A pattern of results was analyzed by repeating at least three
times. p < 0.05 compared with the normal group.
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specimens during the ﬁrst 48 h p.i. (Figure 4A and
B) and remained a high level until 72 h p.i.
(Figure 4C). MIF protein expression was negative
or weakly positive in healthy liver tissues (Figure 4D).
We found a striking accumulation of macrophages
in HCC tissues that may increase the expres-
sion of MIF. These results also showed that the
high intake of
131I-labeled anti-MIF in locus was
consistent with the high expression of MIF in HCC
tissues.
Discussion
HCC is the ﬁfth most common cancer worldwide; its
incidence is very high in China where it is the second
most common cancer. Because many patients are at
increased risk of HCC, there is a need to develop
reliable, sensitive, and speciﬁc imaging markers
that will aid the clinician in early diagnosis. Several
diagnostic modalities such as ultrasound, CT, MRI
have been used to image HCCs; however, there is
no optimal modality to detect this disease at an
early stage. Nuclear medicine has been reported
to play a complementary role in the evaluation of
questionable lesions using high tumor to non-tumor
contrast imaging techniques [14]. Finding an ideal
radiopharmaceutical for the rapid, accurate, and
unequivocal identiﬁcation of HCCs is necessary
in nuclear medicine imaging. Over the past deca-
des, research efforts have been directed toward the
development of monoclonal antibodies as radiophar-
maceuticals for application in ﬁelds of radioimmu-
noimaging [15].
In the present study, overexpression of MIF
mRNA was found in HCC tissues compared with
non-tumor tissues and correlated with the expres-
sion of MIF shown by immunohistology. Consis-
tently, serial images of whole-body autoradiography
showed that the
131I-anti-MIF McAb group had
much more clear images compared with the control
131I-IgG group. MIF is a cytokine produced by
T lymphocytes, macrophages, and tumor cells,
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Figure 4. Expressionof MIF in vivo. Expressionof MIF protein was negative or weakly positive in healthy liver tissues (D). However, there was
a signiﬁcant increase in MIF expression in HCC specimens according to the time after injection in the ﬁrst 48 h (A and B); and keeping the
same level until 72 h (C).
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tion, cell cycle entry, angiogenesis, and tumorigen-
esis, resulting in antigen-speciﬁc immune responses
between
131I-anti-MIF McAb and MIF, while
uptake of
131I-IgG control group in tumor tissues
is caused by nonspeciﬁc binding to Fc fragments of
normal IgG. Although radiolabeled human poly-
clonal IgG had received considerable attention as
a radiopharmaceutical for nuclear medicine imag-
ing [16], it is far from the ideal tumor imaging
reagent because of its lack of speciﬁcity. There are
several novel ﬁndings in this study. First, this is the
ﬁrst report using radioiodinated anti-MIF McAb to
demonstrate that the positive MIF expression in
HCC tissues correlates with a signiﬁcantly high
MIF mRNA expression. Second, radioiodinated
anti-MIF McAb was used as a prospective HCC
imaging agent and provided clear image in tumor
radioimmunoimaging.
MIF was originally described as a lymphokine
involved in delayed hypersensitivity and various
macrophage functions, including production of
proinﬂammatory cytokines, glucocorticoid-induced
immunomodulator, as well as induction of metallo-
proteinase. Furthermore, MIF is suggested to play a
tumorigenic role because of its ability to drive activa-
tion responses by sustaining ERK1 and ERK2 MAP-
kinase activation and by suppressing p53-dependent
growth arrest and apoptosis; these functions sug-
gest that MIF promotes malignant progression of
tumors. Several studies have documented that MIF
is expressed in the sera and liver of patients with
HCC. Intracellular MIF mRNA and protein were
found to be overexpressed in HCC. Patients with
high MIF-expressing tumors had a worse disease-
free survival [17]. These ﬁndings indicated that the
HCC-progressive effect of MIF may be attributable to
its action in inducing tumor-associated angiogenesis,
immunomodulation, and alterations in the tumor
suppressive pathway. The potential of an anti-MIF
therapeutic strategy [18,19] has been highlighted
by the ability of a neutralizing anti-MIF McAb to
attenuate pro-inﬂammatory cytokine production.
Therefore, MIF is considered as a potential target
protein in many pathophysiological states.
Our study showed that the
131I-anti-MIF McAb
has a high target-to-background ratio and has rela-
tively low level of accumulation in non-target tis-
sues, that its expression is highly associated with
the local expression of MIF, and that it is consid-
erably better than nonspeciﬁc IgG for detecting
HCCs by radioimmunoimaging. Hence, we propose
that MIF may be a good marker for early HCC
detection.
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